Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. Hence the study was planned to evaluate the efficacy of tenofovir and entecavir for the treatment of nucleos (t) ide-naïve patients with chronic hepatitis B patients. The study was planned in the 20 patients positive for the hepatitis B surface antigens and aged 20 -70 years old. The study was conducted in the Department of Pharmacology in ANMCH Gaya. The patients were receiving the tenofovir and entecavir for the treatment of nucleos (t) ide-naïve for chronic hepatitis B. In conclusion, tenofovir is more effective than entecavir for achieving CVS in antiviral treatment (mainly with nucleoside analogues)-experienced CHB patients. Consequently, tenofovir may represent a more favourable therapeutic option with regard to durability, as well as efficacy, in these patients, while careful monitoring for the development of resistance is suggested for patients on entecavir monotherapy.